Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
HealthExec zooms in on laws passed in Massachusetts, Oregon and California that are set to change how hedge funds interact with patient care organizations.
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
The billing and practice management services declined to confirm the exact size of its commitment. However, it is listed on the ACR’s website as a “Partner,” a distinction reserved for companies that contribute a half million or more
Governor Tom Corbett has signed the Breast Density Notification Act into law, making Pennsylvania the 13th state to require mammogram results sent to patients to include breast density information
Supporters of the mandatory inclusion of breast density information in patient mammogram result notifications are making another run at getting a national law passed to require this of all imaging providers
The value of scale became evident this year as the largest practices also reported the greatest revenue per FTE radiologist, and the revenue number stepped down with each descending practice-size category
On Wednesday, October 30, the House Ways and Means and Senate Finance Committees jointly released a draft version of policy to replace the sustainable growth rate formula (SGR), and language regarding the use of appropriateness criteria in ordering of advanced medical imaging was included
After a second quarter that was so bad, Merge’s own CEO, Justin Dearborn, called the results “unacceptable” and apologized to investors, the company’s third quarter results were less dramatic, but still not very inspiring to investors
The FDA has approved the GE Healthcare diagnostic imaging tracer flutemetamol F18 (Vizamyl) for use in evaluating adults for Alzheimer's disease and dementia
Imaging providers anxious to see if CMS will drop the proposed separate cost centers for CT and MRI from the final 2014 HOPPS fee schedule will have to wait a little longer